By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > GMJ Briefs > Only 2.2% Difference: Landmark Trial Redefines Chiari Surgery Benchmarks

Only 2.2% Difference: Landmark Trial Redefines Chiari Surgery Benchmarks

GMJ
Last updated: 11/06/2026 13:27
By
Prof. Giorgi Pkhakadze
Share
1 Min Read
Medical illustration of Chiari I malformation surgical decompression procedure
Major NEJM trial shows adding duraplasty to decompression surgery provides only 2.2% additional benefit for Chiari I patients. Both procedures achieved over 60% success rates at 24 months. — Photo: Anna Shvets / Pexels
SHARE
1 min read|127 words

A comprehensive multicenter trial has quantified the incremental benefit of duraplasty in Chiari I surgery with striking precision: just 2.2 percentage points separate the two surgical approaches at 24-month follow-up. The landmark study, published in The New England Journal of Medicine, tracked 65.3% success rates for decompression with duraplasty versus 63.1% for decompression alone in patients with syringomyelia. This minimal difference challenges decades of surgical convention, suggesting that the addition of duraplasty may not justify the increased operative complexity and potential associated risks for many patients. Both groups demonstrated robust clinical outcomes exceeding 60% success, with comparable safety profiles showing serious complications in fewer than 5% of cases. The data indicates that surgeon expertise and patient-specific factors may carry greater weight in determining outcomes than the addition of this technically demanding procedure.

Was this article helpful?

GMJ Brief · Key Finding

📰 Read the full article: Major Trial Finds Minimal Benefit of Duraplasty for Chiari I Surgery →

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Yemen Food Crisis: 11.2 Million Face Acute Hunger as International Aid Funding Cuts Continue

Nearly 11.2 million Yemenis face severe acute food insecurity as international humanitarian…

Two Weather Patterns Linked to Increased Headache Risk in New Study

University of Cincinnati researchers, collaborating with Mount Sinai, Errex Inc., and Teva…

Cancer’s Stealth Strategy Backfires, Creating New Therapeutic Target

Groundbreaking research reveals that cancer cells' common strategy to evade immune detection…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

SITUATION BRIEF: Ebola Outbreak – Democratic Republic of Congo with Cross-Border Transmission to Uganda

By
Prof. Giorgi Pkhakadze
31/05/2026
Healthcare workers in Nigeria providing primary care services

From Crisis to Progress: How One Leader Rebuilt Nigeria’s Neglected Healthcare System

By
Prof. Giorgi Pkhakadze
06/06/2026
Medical illustration showing iron transport pathways and copper enzyme checkpoints in human metabolism

Announcement: Iron Transport Requires Copper at Three Critical Checkpoints, Study Shows

By
Prof. Giorgi Pkhakadze
03/06/2026

EBOLA OUTBREAK: Cross-border transmission from DRC to Uganda triggers WHO PHEIC declaration

By
Prof. Giorgi Pkhakadze
31/05/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up